Highlights to be presented at Novo’s Capital Markets Day 2026

Summary by AI BETAClose X

Novo Nordisk announced its strategic ambitions for 2030 at its Capital Markets Day, aiming to launch over five multi-blockbuster drugs by 2030, projecting over 150 billion Danish Kroner in pipeline sales by 2035, and advancing at least five Phase 3 programs in obesity and diabetes, alongside five in other therapy areas. The company intends to deliver revenue compound annual growth rate in line with industry peers between 2026 and 2030, scale capacity to serve ten times more people with oral GLP-1 for obesity, and reach over 60 million patients globally by 2030, while maintaining a broadly stable operating margin and an attractive dividend per share.

Disclaimer*

UK 100

Latest directors dealings